Physician profile
Michael S Frank
NPI 1982764510
$3,466.62
in general payments reported to CMS, 2019-2025
13 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $277 · 2021: $354 · 2022: $853 · 2023: $941 · 2024: $662 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,758.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,496.28 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $1,325.19 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $143.88 | 2023-2024 | Quviviq |
| Glaxosmithkline, LLC. | $133.03 | 2019-2024 | Arexvy |
| Lilly USA, LLC | $86.36 | 2024-2025 | Zepbound, Jardiance |
| Janssen Biotech, INC. | $73.83 | 2022-2023 | Stelara |
| Ironwood Pharmaceuticals, INC | $62.83 | 2020-2021 | |
| Novo Nordisk INC | $61.95 | 2025 | Wegovy |
| Sanofi Pasteur INC. | $29.48 | 2019-2020 | |
| Exact Sciences Corporation | $16.29 | 2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $13.33 | 2023 | Entyvio |
| Allergan, INC. | $12.19 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.